Comparison of Efficacy, Safety, and Tolerability of Neoral vs Sandimmun in De Novo Renal Transplant Patients Over 24 Months' Treatment

By Abendroth D.   Buchholz B.   Land W.   May G.   Wiesel M.   Farber L.   Korn A.   Maibucher A.  

Transplantation Proceedings, Vol. 29, Iss. 1, 1997-02 ,pp. : 275-276

Elsevier

Access to resources Recommend Favorite

Mycophenolate mofetil/neoral/steroid vs neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients

By Carmellini M.   Vistoli F.   Bellini R.   Boggi U.   Rindi P.   Rizzo G.   Mosca F.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 1162-1164

Elsevier

Access to resources Recommend Favorite

Safety and efficacy of conversion from once daily sandimmun to twice daily neoral cyclosporine in renal allograft recipients

By Vathsala A.   Lee W.T.   Lu Y.-M.   Woo K.T.  

Transplantation Proceedings, Vol. 30, Iss. 5, 1998-08 ,pp. : 1746-1748

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic study of twice vs thrice daily dosing of sandimmun neoral in pediatric renal transplant patients - A New Formulation of Ciclosporine

By Papachristou F.   Gakis D.   Sotiriou I.   Liatsis I.   Takoudas D.   Antoniadis A.  

Transplantation Proceedings, Vol. 30, Iss. 5, 1998-08 ,pp. : 1988-1990

Elsevier

Access to resources Recommend Favorite

Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients

By Shah M.H.   Bokhari M.Z.M.   Bokhari M.T.M.   Farooq A.   Yousaf S.M.  

Transplantation Proceedings, Vol. 35, Iss. 7, 2003-11 ,pp. : 2737-2738

Elsevier

Access to resources Recommend Favorite